The indictment issued by the Federal Court in Abingdon, Virginia, indicates that Indivior – which until 2014 was part of the Reckitt Benckiser group – has sought to take advantage of the deep opiate crisis affecting the United States. Particularly exaggerating the safety of its drug Suboxone.
According to the document, the laboratory began in 2010 to falsely assure health professionals that its treatment, containing opioid buprenorphine, was more effective and less dangerous than similar drugs.
He is also accused of launching a program to connect patients with doctors “known to prescribe Suboxone and / or other opiates with negligence and without clinical justification”.
Indivior, quoted on the London Stock Exchange and headquartered in Richmond, Virginia, said in a statement its intention to “defend vigorously” against charges “not corroborated by the facts or the law.”